LIGAND PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net income (loss) | $124,453 | $(4,032) | $52,154 |
| Unrealized net gain on available-for-sale securities, net of tax | 181 | 45 | 167 |
| Foreign currency translation adjustment, net of tax | 14,216 | (5,170) | — |
| Comprehensive income (loss) | $138,850 | $(9,157) | $52,321 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.